找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Diagnosis and Management of Testicular Cancer; The European Point o Susanne Krege Book 2015 Springer International Publishing Switzerland 2

[復(fù)制鏈接]
樓主: Iodine
21#
發(fā)表于 2025-3-25 03:52:49 | 只看該作者
22#
發(fā)表于 2025-3-25 11:13:56 | 只看該作者
23#
發(fā)表于 2025-3-25 12:47:16 | 只看該作者
24#
發(fā)表于 2025-3-25 19:02:57 | 只看該作者
https://doi.org/10.1007/978-1-4842-9830-5ying from recurrent TC or a second cancer, TCS have a 6 % increased risk of mortality from non-cancer causes, including infections, cardiovascular disease (CVD), and respiratory disease after cisplatin-based chemotherapy compared with the general population [2].
25#
發(fā)表于 2025-3-25 20:56:49 | 只看該作者
Latest Recommendations of the European Germ Cell Cancer Group on Diagnosis and Treatment of Germ Cel9, 2004). The consensus group consisted of more than 60 experts from all across Europe. The experts involved were oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists. Since then, regular updates were performed by the group (Krege et al. Eur Urol 53:478–496, 2008; Kreg
26#
發(fā)表于 2025-3-26 03:41:47 | 只看該作者
27#
發(fā)表于 2025-3-26 07:50:14 | 只看該作者
Is There Still an Indication for Primary RPLND in Clinical Stage I Non-seminoma? A significant proportion (about two thirds) of patients with ascertained small nodal metastases at RPLND, are cured by surgery with no need of further therapy..The introduction of effective cisplatin-based chemotherapy has progressively reduced the role of primary RPLND in early stages NSGCT. This
28#
發(fā)表于 2025-3-26 12:28:34 | 只看該作者
29#
發(fā)表于 2025-3-26 12:37:50 | 只看該作者
Poor-Prognosis Germ Cell TumoursCT, extra-pulmonary visceral metastases or very high serum tumour marker levels (hCG > 50,000 UI/L, AFP > 10,000 ng/mL and/or LDH > 10 times the upper limit value). This subgroup of 10% patients is responsible for most of the deaths from GCT. Their progression-free survival rate is 41 % with only ha
30#
發(fā)表于 2025-3-26 18:59:16 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 14:51
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
古蔺县| 米脂县| 甘泉县| 诸城市| 庆城县| 施秉县| 石嘴山市| 新龙县| 城步| 晋中市| 禄丰县| 汉沽区| 厦门市| 于都县| 肥东县| 汕头市| 资源县| 田东县| 庄浪县| 维西| 通江县| 沂源县| 柳河县| 西乌| 桂林市| 德安县| 宁河县| 高要市| 宁阳县| 七台河市| 冀州市| 石阡县| 伊春市| 韩城市| 宜都市| 广灵县| 黄石市| 斗六市| 确山县| 沾益县| 铁岭市|